Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Baby with deadly spine condition gets world’s costliest gene therapy

A five-month old baby has become the first patient to receive a potentially life-saving drug on the NHS that can prevent paralysis and prolong the lives of children with Spinal Muscular Atrophy (SMA).

Arthur Morgan, who was diagnosed with SMA last month, received the one-off gene therapy at Evelina London Children’s Hospital on May 25.


The drug, Zolgensma, which has a list price of £1.795m per single dose, was made available on the NHS following a deal with manufacturers Novartis in March.

Baby Arthur, who was born six weeks premature in December, underwent the gene therapy infusion last week after being diagnosed with SMA less than three weeks earlier.

Babies born with type 1 SMA experience progressive muscle weakness, loss of movement, difficulty breathing, with a life expectancy of just two years.

Health secretary Matt Hancock said: “I am so glad young Arthur can access this potentially life-changing treatment on the NHS. I hope it grants his family and many others renewed hope that more children’s lives can be transformed.

“Through the NHS Long Term Plan, we are doing everything we can to provide people with access to the latest generation of innovative medicines though the NHS.

“Arthur’s story is the latest example of our brilliant life sciences industry working hand in hand with the NHS to put patients first.”

Dr Elizabeth Wraige, consultant paediatric neurologist at Evelina London Children’s Hospital, said: “Babies like Arthur, who is first to receive this treatment in England, may now be able to have a one-off gene therapy to treat the root cause of SMA with the aim of preventing the further progression or even onset of this debilitating condition. This treatment will bring hope to families affected by SMA who have fought so courageously against it. ”

Sally-Anne Tsangarides, general manager at Novartis in the UK, said: “Novartis is delighted to be part of this remarkable milestone – it is a hugely important step for babies in England diagnosed with this devastating genetic condition and we thank all those who have been involved in the landmark agreement that has made it possible.”

More For You

Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less
Pharmacy students Learning Support Fund

Pharmacy students will be included in the Travel and Dual Accommodation Expenses section of the NHS Learning Support Fund.

iStock

Pharmacy students to have access to Learning Support Fund

FOR the first time in England, pharmacy students will be eligible to reimburse travel and accommodation costs while attending placements.

The Department of Health and Social Care confirmed that pharmacy students would finally be included in the Travel and Dual Accommodation Expenses (TDAE) section of the NHS Learning Support Fund (LSF).

Keep ReadingShow less
NHS for robotic surgery

Patients undergoing robotic surgery are able to recover quicker and be discharged sooner.

Pic credit: iStock

NHS pushes for robotic surgery to reduce waiting time, improve outcomes

The NHS is planning to step up robotic surgery over the next decade to reduce waiting time, help in the speed of recovery of patients, and shorter hospital stay.

As per the NHS projections, the number is expected to zoom from 70,000 in 2023/24 to half a million by 2035.

Keep ReadingShow less
Scotland's digital patient care record

The amendment ensures that every person who receives health care or a social service in Scotland will have a digital care record

Pic credit: iStock

Scotland's move to create digital patient care record hailed

The Royal Pharmaceutical Society (RPS) in Scotland has welcomed the decision of the Scottish Parliament to create an integrated digital patient care record.

The move came during a debate on the Care Reform (Scotland) Bill on Tuesday (10), when Jackie Baillie tabled an amendment to ensure that every person who receives health care or a social service in Scotland has a digital care record.

Keep ReadingShow less
A woman using a period tracker app

Cambridge University academics have flagged concerns over the safety of period tracker apps

Pic credit: iStock

Users of period tracking apps face privacy, safety risk, say experts

The report said the apps provide a "gold mine" of data for consumer profiling and warn that in the wrong hands it could pose a safety risk

CAMBRIDGE UNIVERSITY academics have flagged concerns over the safety of period tracker apps and warned that the women using them could face privacy and safety risks.

Keep ReadingShow less